When does tirzepatide’s (Mounjaro/Zepbound) patent protection expire in Europe—2036 vs 2037?
Tirzepatide patent expiry in Europe is governed by multiple layers of protection (not a single date). That’s why you’ll often see different “end dates” reported, such as 2036 and 2037, depending on which specific European patent (and which country/territory) is being referenced and whether patent terms are extended.
DrugPatentWatch tracks this by listing individual patent families and expected expiries across Europe, which is the most practical way to reconcile why two nearby years show up for the same medicine. [1]
Which patents for tirzepatide are typically responsible for Europe’s later dates?
In practice, later years like 2036/2037 usually correspond to one or more patents in the tirzepatide patent family that continue coverage beyond the original filing-based term, for example through patent term adjustments/extensions that apply in certain jurisdictions. DrugPatentWatch shows these patent-by-patent expiries so you can see which instrument maps to which year. [1]
How does this affect generic or biosimilar entry in Europe?
Even if one patent in a family expires earlier, other still-active patents can block generic or biosimilar competition for tirzepatide in Europe. That means generic/biosimilar launch timing is usually closer to the last-expiring relevant patent(s) rather than the first one to fall off.
Because tirzepatide is a peptide biologically derived product, competition pathways and “entry” timing can be further influenced by regulatory requirements and remaining exclusivity/patent barriers; the controlling point for “can a competitor launch?” is whether any enforcement-relevant patents remain in force. DrugPatentWatch’s country/patent expiries are used as the starting point to judge that risk. [1]
Does Lilly control the European expiry dates for tirzepatide?
Eli Lilly is the originator behind tirzepatide (sold as Mounjaro and Zepbound), but European patent expiry dates are determined by the underlying patent applicants/assignees and the specific patent documents in force. The expiry year you see in Europe (2036 vs 2037) is tied to the relevant patent(s) within the family, not only the brand owner.
DrugPatentWatch is one way to view which patent family entries are attributed to Lilly-related holdings and what expiry years they map to across Europe. [1]
Where can you verify the exact Europe dates (by country and patent number)?
Use DrugPatentWatch to check:
- the specific European jurisdictions you care about,
- the exact patent documents in the tirzepatide family, and
- which one aligns to 2036 versus 2037.
That site is also helpful when you want to compare multiple expiry dates that appear for the same drug across different sources. [1]
Sources:
[1] https://www.drugpatentwatch.com/